Prasanna Srinivasan Ramalingam

Dr. Prasanna Srinivasan Ramalingam

School of Biosciences and Technology, Vellore Institute of technology (VIT), Vellore, India
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Natural Remedies
Verified
Journal Article
Open access
PDF file
BPBalakrishnan Purushothaman
Balakrishnan Purushothaman
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
PSPurushothaman Suganthi
Purushothaman Suganthi
BRBalu Ranganathan
Balu Ranganathan
Jolius GimbunJolius Gimbun
Jolius Gimbun
SLShowcase Lane Palms Connect Llc
Showcase Lane Palms Connect Llc
A Comprehensive Review on Ocimum basilicum

10 March 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
JMJanaki Ramaiah Mekala
Janaki Ramaiah Mekala
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
SMSivagami Mathavan
Sivagami Mathavan
RYRajesh B.R.D. Yamajala
Rajesh B.R.D. Yamajala
NMNageswara Rao Moparthi
Nageswara Rao Moparthi
RMRajasekhar Reddy Manyam
Rajasekhar Reddy Manyam

14 March 2024 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
SESujatha Elangovan
Sujatha Elangovan
JMJanaki Ramaiah Mekala
Janaki Ramaiah Mekala
SASIVAKUMAR ARUMUGAM
SIVAKUMAR ARUMUGAM
Cancer has become a serious health burden that results in high incidence and mortality rates every year, mainly due to various molecular alterations inside the cell. Liver X receptors (LXRs) dysregulation is one among them that plays a vital role in cholesterol metabolism, lipid metabolism and inflammation and also plays a crucial role in various diseases such as obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), cardiovascular diseases, Type 2 diabetes, osteoporosis, and cancer. Studies report that the activation of LXRs inhibits cancer growth by inhibiting cellular proliferation, inducing apoptosis and autophagy, regulating cholesterol metabolism, various signalling pathways such as Wnt, and PI3K/AKT, modulating the expression levels of cell-cycle regulators, and promoting antitumor immunity inside the tumor microenvironment. In this review, we have discussed the role, structure, and functions of LXRs and also summarized their ligands along with their mechanism of action. In addition, the role of LXRs in various cancers, tumor immunity and tumor microenvironment (TME) along with the importance of precision medicine in LXR-targeted therapies has been discussed to emphasize the LXRs as potent targets for the development of novel cancer therapeutics.

Verified
Journal Article
Open access
PDF file
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
PBPurushothaman Balakrishnan
Purushothaman Balakrishnan
SRSenthilnathan Rajendran
Senthilnathan Rajendran
AJArunachalam Jothi
Arunachalam Jothi
RRRajasekaran Ramalingam
Rajasekaran Ramalingam
SASIVAKUMAR ARUMUGAM
SIVAKUMAR ARUMUGAM
The KRAS G12D mutation is very frequent in many cancers, such as pancreatic, colon and lung, and has remained undruggable for the past three decades, due to its smooth surface and lack of suitable pockets. Recent small pieces of evidence suggest that targeting the switch I/II of KRAS G12D mutant could be an efficient strategy. Therefore, in the present study, we targeted the switch I (residues 25–40) and switch II (residues 57–76) regions of KRAS G12D with dietary bioflavonoids in comparison with the reference KRAS SI/II inhibitor BI-2852. Initially, we screened 925 bioflavonoids based on drug-likeness properties, and ADME properties and selected 514 bioflavonoids for further studies. Molecular docking resulted in four lead bioflavonoids, namely 5-Dehydroxyparatocarpin K (L1), Carpachromene (L2), Sanggenone H (L3), and Kuwanol C (L4) with binding affinities of 8.8 Kcal/mol, 8.64 Kcal/mol, 8.62 Kcal/mol, and 8.58 Kcal/mol, respectively, in comparison with BI-2852 (−8.59 Kcal/mol). Further steered-molecular dynamics, molecular-dynamics simulation, toxicity, and in silico cancer-cell-line cytotoxicity predictions significantly support these four lead bioflavonoids as potential inhibitors of KRAS G12D SI/SII inhibitors. We finally conclude that these four bioflavonoids have potential inhibitory activity against the KRAS G12D mutant, and are further to be studied in vitro and in vivo, to evaluate their therapeutic potential and the utility of these compounds against KRAS G12D mutated cancers.

29 September 2023 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
SASIVAKUMAR ARUMUGAM
SIVAKUMAR ARUMUGAM

8 March 2025 in Clinical Breast Cancer
Verified
Journal Article
Closed access
MHMd Sadique Hussain
Md Sadique Hussain
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
GCGayathri Chellasamy
Gayathri Chellasamy
KYKyusik Yun
Kyusik Yun
ABAjay Singh Bisht
Ajay Singh Bisht
GGGaurav Gupta
Gaurav Gupta